124 related articles for article (PubMed ID: 2453486)
1. In vitro effects of diethylstilboestrol and the LHRH analogue leuprolide on natural killer cell activity.
Ablin RJ; Bartkus JM; Gonder MJ
Immunopharmacology; 1988; 15(2):95-101. PubMed ID: 2453486
[TBL] [Abstract][Full Text] [Related]
2. Leuprolide vs. diethylstilboestrol: effect on natural killer cells.
Ablin RJ; Gonder MJ; Bartkus JM
Anticancer Res; 1988; 8(1):73-6. PubMed ID: 3128959
[TBL] [Abstract][Full Text] [Related]
3. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
Garnick MB
Urology; 1986 Jan; 27(1 Suppl):21-8. PubMed ID: 3079935
[TBL] [Abstract][Full Text] [Related]
4. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
Leuprolide Study Group
N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700
[TBL] [Abstract][Full Text] [Related]
5. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate.
Stein BS; Smith JA
Urology; 1985 Apr; 25(4):350-3. PubMed ID: 3920802
[TBL] [Abstract][Full Text] [Related]
6. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.
Sharifi R; Lee M; Ojeda L; Ray P; Stobnicki M; Guinan P
Urology; 1985 Aug; 26(2):117-24. PubMed ID: 3927551
[TBL] [Abstract][Full Text] [Related]
7. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
Garnick MB; Glode LM; Smith JA; Max DT
Br J Clin Pract; 1985 Feb; 39(2):73-6. PubMed ID: 3921047
[No Abstract] [Full Text] [Related]
8. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
Garnick MB; Glode LM; Smith JA; Max DT
Br J Clin Pract Suppl; 1985 Mar; 37():8-12, 20-4. PubMed ID: 3931665
[No Abstract] [Full Text] [Related]
9. Effects of diethylstilbestrol on human natural killer cells in vitro.
Kalland T; Campbell T
Immunopharmacology; 1984 Aug; 8(1):19-25. PubMed ID: 6436192
[TBL] [Abstract][Full Text] [Related]
10. A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.
Winfield H; Trachtenberg J
J Urol; 1984 Jun; 131(6):1107-9. PubMed ID: 6427477
[TBL] [Abstract][Full Text] [Related]
11. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
Smith JA
J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of gonadotropin-releasing hormone agonist on natural killer cell cytolysis in women with and without endometriosis.
Wong KH; Simon JA
Am J Obstet Gynecol; 2004 Jan; 190(1):44-9. PubMed ID: 14749633
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
16. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
[TBL] [Abstract][Full Text] [Related]
17. LHRH analogues in the treatment of prostatic cancer. Introduction.
Dufour B
Br J Clin Pract Suppl; 1985 Mar; 37():2-3, 14-5. PubMed ID: 3931663
[No Abstract] [Full Text] [Related]
18. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
Yamanaka H; Makino T; Kumasaka F; Shida K
Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
[TBL] [Abstract][Full Text] [Related]
19. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
